1: (ROOT (S (S (NP (NNP Melatonin)) (VP (MD Could) (ADVP (RB Possibly)) (VP (VB Play) (NP (DT An) (ADJP (JJ Immune) (VBG Modulating)) (NN Role)) (PP (PP (IN Against) (NNP COVI-19A)) (S (NP (JJ recent) (NN review)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN melatonin)) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG combating) (NP (CD COVI-19)) (PP (IN as) (NP (DT an) (NN adjuvant) (NN therapy)))))))))))))))) (: ;) (S (S (NP (NP (JJ excessive) (NN inflammation)) (, ,) (NP (NN oxidation)) (, ,) (CC and) (NP (NP (JJ exaggerated) (JJ immune) (NNS responses)) (PP (IN during) (NP (NN infection))))) (VP (VBZ contributes) (PP (IN to) (NP (NP (DT the) (NN cytokine) (NN storm)) (SBAR (WHNP (WDT that)) (S (VP (VBZ progresses) (PP (IN into) (NP (NP (JJ acute) (NN lung) (NN injury)) (CC and) (NP (NML (JJ acute) (JJ respiratory) (NN distress)) (NN syndrome))))))))))) (CC and) (NP (NP (NP (DT the) (UCP (NN antioxidant) (, ,) (NN ant) (HYPH -) (JJ inflammatory) (, ,) (CC and) (VBG immunomodulating)) (NNS effects)) (PP (IN of) (NP (NN melatonin)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ protective) (PP (IN against) (NP (ADJP (JJ viral) (VBN induced)) (NNP ALI) (CC and) (NNPS ARDS)))))))))))) (. .)))
2: (ROOT (S (NP (NN Research)) (VP (VBZ indicates) (NP (NP (NP (NN nucleotide) (NN similarity)) (PP (IN between) (NP (NP (NNP SAR) (HYPH -) (NNPS COVs)) (, ,) (NP (NNP MER) (HYPH -) (NNPS CoVs)) (CC and) (NP (NNP SAR) (HYPH -) (NNP CoV02))))) (SBAR (WHNP (WDT which)) (S (VP (VBZ suggests) (NP (DT a) (JJ high) (JJ genetic) (NN homology))))))) (. .)))
3: (ROOT (S (PP (IN With) (NP (NN infection))) (NP (JJ severe) (ADJP (JJ inflammatory) (CC and) (JJ immune)) (NN response)) (VP (MD may) (VP (VB activate) (NP (NP (NP (DT a) (NN cytokine) (NN storm)) (PP (JJ such) (IN as) (NP (NP (NN apoptosis)) (PP (IN of) (NP (NP (JJ epithelial) (NNS cells)) (CC and) (NP (JJ endothelial) (NNS cells))))))) (VP (VBG leading) (PP (IN to) (NP (NP (JJ vascular) (NN leakage)) (CC and) (NP (NP (JJ abnormal) (NML (NN -cell) (CC and) (NML (NN macrophage))) (NNS responses)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB induce) (NP (NP (NNP AL) (SYM /) (NNP ARDS)) (CC and) (RB even) (NP (NN death)))))))))))))) (. .)))
4: (ROOT (S (S (NP (DT This) (NN storm)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (ADJP (JJ prevalent)) (PP (IN in) (NP (NP (NP (DT those)) (PP (IN with) (NP (HYPH COVI-19)))) (PP (VBN based) (PP (IN on) (NP (NP (JJ genetic) (NN homology)) (CC and) (NP (NP (JJ pathologic) (NNS features)) (PP (IN of) (NP (JJ infected) (NNS lungs)))))))))))))) (, ,) (CC and) (S (PP (IN in) (NP (DT the) (NN blood))) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS markers)) (NML (NNP I-1B) (, ,) (NP (NNP IF) (HYPH -) (NN y)) (, ,) (NP (CD I-10)) (, ,) (HYPH MC-1) (, ,) (CD I-4) (CC and) (NML (CD I-10)))))))) (. .)))
5: (ROOT (S (NP (NP (DT Those)) (PP (IN with) (NP (CD COVI-19)))) (ADVP (RB also)) (VP (VBP present) (PP (IN with) (NP (NP (VBN suppressed) (JJ immune) (NN function)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN marked) (PP (IN by) (NP (NP (NN hyp) (HYPH -) (NN albuminemia)) (, ,) (NP (NN lymphopenia)) (, ,) (NP (NN neutropenia)) (, ,) (CC and) (NP (NP (DT a) (VBN decreased) (NN percentage)) (PP (IN of) (NP (NML (NN CD8) (HYPH +)) (NNS -cells))))))))))))) (. .)))
6: (ROOT (S (NP (DT The) (NML (NML (JJ excessive) (NN inflammation)) (, ,) (NML (JJ depressed) (NN immunity)) (, ,) (CC and) (NML (NN cytokine) (NN storm)))) (VP (VBP appear) (S (VP (TO to) (VP (VB contribute) (PP (IN to) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (CD COVI-19))))))))) (. .)))
7: (ROOT (S (S (PP (IN Due) (IN to) (NP (DT the) (ADJP (JJ antiviral) (, ,) (NN antioxidant) (, ,) (CC and) (ADJP (NN immune) (VBG enhancing))) (NNS properties))) (NP (NN melatonin)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB help) (S (VP (VB reduce) (NP (NN viremia) (, ,) (NN paralysis) (, ,) (CC and) (NN death)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN infected) (PP (IN with) (NP (NN encephalitis))))))))))))))) (CC and) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN led) (PP (IN to) (NP (NP (DT the) (NN downregulation)) (PP (IN of) (NP (NP (JJ acute) (NN lung) (JJ oxidative) (NN injury)) (, ,) (NP (NML (JJ proinflammatory) (NN cytokine)) (NN release)) (CC and) (NP (NML (JJ inflammatory) (NN cell)) (NN recruitment)))) (PP (IN in) (NP (NML (JJ respiratory) (JJ syncytial) (NN virus)) (NNS models)))))))) (. .)))
8: (ROOT (S (S (NP (NNS Findings)) (VP (VBP support) (NP (NP (JJ possible) (NN use)) (PP (IN of) (NP (NN melatonin))) (PP (IN in) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ viral) (NNS diseases)))))))) (, ,) (S (ADVP (RB additionally)) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NN melatonin) (NN support)))) (VP (VBZ has) (NP (NP (JJ potential) (NN attenuation)) (PP (IN for) (NP (HYPH COVI-19) (NN infection)))))) (. .)))
9: (ROOT (S (NP (DT The) (ADJP (NN ant) (HYPH -) (JJ inflammatory)) (NNS effects)) (VP (VBP are) (VP (VBN exerted) (PP (IN through) (NP (NP (JJ various) (NNS pathways)) (PP (JJ such) (IN as) (S (VP (VP (VBG suppressing) (NP (NP (NML (NNP N) (HYPH -) (NN kB)) (NN activation)) (PP (IN in) (NP (NNP ARDS))))) (CC and) (VP (VBG downregulating) (NP (NP (NML (NNP N) (HYPH -) (NN kN)) (NN activation)) (PP (IN in) (NP (NP (NNS -cells)) (CC and) (NP (NN lung) (NNS tissues))))))))))))) (. .)))
10: (ROOT (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ stimulates) (NP (NP (NP (NN N) (HYPH -) (NN E3)) (VBN related) (NN factor) (CD 2)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ important) (PP (IN in) (S (VP (VBG protecting) (PP (IN against) (NP (NN lung) (, ,) (NN liver) (, ,) (CC and) (JJ cardiovascular) (NN injury)))))))))))) (. .)))
11: (ROOT (S (NP (NN Melatonin)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB help) (S (VP (VB reduce) (NP (NP (NN production)) (PP (IN of) (NP (NP (DT the) (NNS cytokines) (CC and) (NNS chemokines) (NP (NN TN) (HYPH -) (NN a) (, ,) (NNP I-1B) (, ,) (CD I-6) (, ,) (CC and) (CD I-8))) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NN inflammation)))))))))))))))))) (. .)))
12: (ROOT (S (NP (CD NLRP3)) (VP (VBZ is) (NP (NP (NN part)) (PP (IN of) (NP (NP (NP (DT the) (JJ innate) (JJ immune) (NN response)) (PP (IN during) (NP (NN lung) (NN infection)))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN activated) (PP (IN by) (NP (NNS viruses))) (S (VP (TO to) (VP (VB amplify) (NP (NN inflammation))))))))))))) (. .)))
13: (ROOT (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN correlated) (PP (IN to) (NP (NP (NN lung) (NN disease)) (VP (VBN caused) (PP (IN by) (NP (NN infection))))))))) (CC and) (S (NP (NN melatonin)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ efficacious) (PP (IN at) (S (VP (VBG inhibiting) (NP (NN NLRP3) (VBN mediated) (NN lung) (NN injury)) (PP (IN by) (S (VP (VBG reducing) (NP (NP (NN inflammation)) (PP (IN of) (NP (NNS macrophages) (CC and) (NNS neutrophils))) (PP (IN in) (NP (NN lung) (NNS tissues)))))))))))))))))) (. .)))
14: (ROOT (S (S (NP (NNP Melatonin)) (VP (VBZ enhances) (NP (JJ immune) (NN response)) (PP (IN by) (S (VP (VBG improving) (NP (NP (NN proliferation) (CC and) (NN maturation)) (PP (IN of) (NP (NP (JJ natural) (NN killer) (NNS cells)) (, ,) (NP (NML (NNP T) (CC and) (NNP B)) (NNS lymphocytes)) (, ,) (NP (NNS granulocytes)) (CC and) (NP (NNS monocytes)))))))))) (: ;) (S (PP (IN in) (NP (NNS macrophages))) (NP (JJ antigen) (NN presentation)) (VP (VBZ is) (VP (VBN augmented) (PP (IN after) (NP (NP (NP (DT the) (NN application)) (PP (IN of) (NP (NN melatonin)))) (PP (VBG including) (NP (NP (DT the) (NN upregulation)) (PP (IN of) (NP (NP (NP (NP (NN complement) (NN receptor)) (CD 3)) (, ,) (NP (NP (NNP MHC) (NN class) (CD I)) (CC and) (NP (NN class) (CD II)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (CD CD4) (NNS antigens))))))))))) (. .)))
15: (ROOT (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (NNS studies)) (VP (VBN related) (PP (IN to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN melatonin))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (CD COVI-19)))))))))))) (NP (PRP$ its) (NN use)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ promising)) (PP (IN in) (NP (NP (JJ other) (NNS diseases)) (PP (IN with) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NN inflammation))))))))))))) (. .)))
16: (ROOT (S (NP (NP (NNS Doses)) (PP (IN of) (NP (NP (QP (CD 5) (CD m) (SYM /)) (NN d)) (CC and) (NP (QP (QP (CD 25) (CD m)) (SYM /)) (NN d))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VP (VB decrease) (NP (NP (JJ serum) (NNS levels)) (PP (IN of) (NP (NP (CD I-6)) (, ,) (NML (NN TB) (HYPH -) (NN a)) (, ,) (CC and) (NP (NML (NN h) (HYPH -) (NN C)) (JJ reactive) (NN protein))))) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (NN diabetes) (NN mellitus) (CC and) (NNS periodontitis)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (VBG promoting) (NP (NP (NP (NP (NNS reductions)) (IN in) (NP (JJ serum) (NNS concentrations))) (IN of) (NP (NP (NNP TN) (HYPH -) (NN a)) (, ,) (NP (CD I-6)) (, ,) (NP (NNP I-1B)) (CC and) (NP (NNS lipoproteins)))) (IN with))))))))) (. M.)))
17: (ROOT (S (S (PP (ADVP (RB Even)) (IN at) (NP (JJR higher) (NNS doses))) (NP (NP (DT the) (JJ short) (NN term) (NN use)) (PP (IN of) (NP (NN melatonin)))) (VP (VBZ has) (VP (VBN been) (VP (VBN deemed) (S (ADJP (JJ safe))))))) (, ,) (CC but) (S (SBAR (IN while) (S (NP (PRP$ their) (NN safety)) (VP (VBZ has) (VP (VBN been) (VP (VBN verified) (PP (IN in) (NP (JJ human) (NNS studies)))))))) (NP (NP (PRP$ its) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN to) (NP (NP (DT those)) (PP (IN with) (NP (CD COVI-19))))))))) (VP (VP (VBZ remains) (ADJP (JJ unknown))) (CC and) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely))))))) (. .)))
18: (ROOT (S (NP (NP (NN Animal) (NNS models)) (CC and) (NP (JJ human) (NNS studies))) (VP (VBP have) (ADVP (RB continuously)) (VP (VBN documented) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NN melatonin)))))) (. .)))
19: (ROOT (S (NP (NP (NP (DT Those)) (PP (IN with) (NP (JJ viral) (NN infection)))) (CC or) (NP (NP (DT those)) (VP (VBG dealing) (PP (IN with) (NP (NP (ADJP (NN inflammation) (VBN based)) (JJ chronic) (NNS conditions)) (ADJP (JJ possible))))))) (VP (MD may) (VP (VB benefit) (PP (IN from) (NP (NN melatonin))))) (. .)))
20: (ROOT (S (ADVP (RB Thus)) (NP (NN melatonin) (NN testing)) (VP (MD could) (VP (VB reveal) (NP (NP (DT the) (JJ baseline) (NN status)) (PP (IN of) (NP (DT this) (ADJP (ADJP (NN ant) (HYPH -) (JJ inflammatory)) (CC and) (ADJP (JJ immune) (VBG modulating))) (NN hormone)))) (S (VP (TO to) (VP (VB provide) (NP (NP (DT a) (NN framework)) (PP (IN for) (NP (PRP$ its) (NN supplementation))))))))) (. .)))
